Literature DB >> 27342144

Role of protein S in castration-resistant prostate cancer-like cells.

Peng Ning1, Jia-Guo Zhong2, Fan Jiang3, Yi Zhang3, Jie Zhao4, Feng Tian5, Wei Li6.   

Abstract

Understanding how castration-resistant prostate cancer (CRPC) cells survive the androgen-deprivation condition is crucial for treatment of this advanced prostate cancer (PCa). Here, we reported for the first time the up-regulation of protein S (PROS), an anticoagulant plasma glycoprotein with multiple biological functions, in androgen-insensitive PCa cells and in experimentally induced castration-resistant PCa cells. Overexpression of exogenous PROS in LNCaP cells reduced androgen deprivation-induced apoptosis and enhanced anchorage-dependent clonogenic ability under androgen deprivation condition. Reciprocally, PROS1 knockdown inhibited cell invasiveness and migration, caused the growth inhibition of castration-resistant tumor xenograft under androgen-depleted conditions, and potentiated Taxol (a widely prescribed anti-neoplastic agent)-mediated cell death in PC3 cells. Furthermore, PROS overexpression significantly stimulated AKT activation but failed to evoke oxidative stress in LNCaP cells under normal condition, suggesting that the malignance-promoting effects of the above-mentioned pathway may occur in the order of oxidative stress/PROS/AKT. The potential mechanism may be due to control of oxidative stress-elicited activation of PI3K-AKT-mTOR pathway. Taken together, our gain-of-function, loss-of-function analyses suggest that PROS may facilitate cell proliferation and promote castration resistance in human castration-resistant PCa-like cells via its apoptosis-regulating property. Future study emphasizing on delineating how PROS regulate cellular processes controlling transformation during the development of castration resistance should open new doors for the development of novel therapeutic targets for CRPC.
© 2016 Society for Endocrinology.

Entities:  

Keywords:  AKT; apoptosis; castration-resistant prostate cancer; oxidative stress; prostate cancer; protein S

Mesh:

Substances:

Year:  2016        PMID: 27342144     DOI: 10.1530/ERC-16-0126

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  8 in total

Review 1.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

2.  Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.

Authors:  Frank C Cackowski; Matthew R Eber; James Rhee; Ann M Decker; Kenji Yumoto; Janice E Berry; Eunsohl Lee; Yusuke Shiozawa; Younghun Jung; Julio A Aguirre-Ghiso; Russell S Taichman
Journal:  J Cell Biochem       Date:  2016-11-10       Impact factor: 4.429

Review 3.  Multiple functions of HuR in urinary tumors.

Authors:  Fa Zhang; Zhonglin Cai; Haidi Lv; Wenjuan Li; Mengtian Liang; Xupan Wei; Fenghai Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-28       Impact factor: 4.553

4.  miR-1271 inhibits ERα expression and confers letrozole resistance in breast cancer.

Authors:  Tao Yu; Hai-Ru Yu; Jia-Yi Sun; Zhao Zhao; Shuang Li; Xin-Feng Zhang; Zhi-Xuan Liao; Ming-Ke Cui; Juan Li; Chan Li; Qiang Zhang
Journal:  Oncotarget       Date:  2017-11-09

5.  Upregulation of PITX2 Promotes Letrozole Resistance Via Transcriptional Activation of IFITM1 Signaling in Breast Cancer Cells.

Authors:  Ying-Ying Xu; Hai-Ru Yu; Jia-Yi Sun; Zhao Zhao; Shuang Li; Xin-Feng Zhang; Zhi-Xuan Liao; Ming-Ke Cui; Juan Li; Chan Li; Qiang Zhang
Journal:  Cancer Res Treat       Date:  2018-07-18       Impact factor: 4.679

6.  MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.

Authors:  Cheng Wu; Chunqing Miao; Qingsheng Tang; Xunrong Zhou; Pengshan Xi; Ping'an Chang; Lixin Hua; Haodong Ni
Journal:  J Cell Mol Med       Date:  2019-12-26       Impact factor: 5.310

7.  BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas.

Authors:  Christopher J Kaler; James J Dollar; Anthony M Cruz; Jeffim N Kuznetsoff; Margaret I Sanchez; Christina L Decatur; Jonathan D Licht; Keiran S M Smalley; Zelia M Correa; Stefan Kurtenbach; J William Harbour
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

8.  AXL, along with PROS1, is overexpressed in papillary thyroid carcinoma and regulates its biological behaviour.

Authors:  Mingze Wei; Yizeng Wang; Yuanchao Liu; Dongyang Li; Xianghui He
Journal:  World J Surg Oncol       Date:  2022-10-06       Impact factor: 3.253

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.